Gavilimomab
| Gavilimomab?
| |
| Therapeutic monoclonal antibody | |
| Source | Mouse |
| Target | CD147 |
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | ? |
| Chemical data | |
| Formula | ? |
| Mol. mass | ? |
| Pharmacokinetic data | |
| Bioavailability | ? |
| Metabolism | ? |
| Half life | ? |
| Excretion | ? |
| Therapeutic considerations | |
| Pregnancy cat. |
? |
| Legal status | |
| Routes | ? |
Gavilimomab is a mouse monoclonal antibody (also known as ABX-CBL) is an immunosuppresive drug. It binds to antigen CD147.
Mouse monoclonal antibodies ("-o-") | |
|---|---|
| "govo" (ovarian tumor) | Abagovomab, Igovomab, Oregovomab |
| "limo" (immune system) | Afelimomab, Dorlimomab aritox, Elsilimomab, Faralimomab, Gavilimomab, Inolimomab, Maslimomab, Nerelimomab, Odulimomab, Telimomab aritox, Vepalimomab, Zolimomab aritox |
| "tumo" (miscellaneous tumor) | Altumomab, Anatumomab mafenatox, Arcitumomab, Bectumomab, Detumomab, Epitumomab, Epitumomab cituxetan, Ibritumomab tiuxetan, Minretumomab, Mitumomab, Naptumomab estafenatox, Nofetumomab merpentan, Pemtumomab, Pintumomab, Satumomab, Taplitumomab paptox, Tositumomab |
| "leso" (infectious lesions) | Besilesomab, Fanolesomab, Lemalesomab, Sulesomab |
| "ciro" (cardiovascular) | Biciromab brallobarbital, Imciromab |
| "pro" (prostate tumor) | Capromab |
| "baco" (bacterial) | Edobacomab |
| "colo" (colonic tumor) | Edrecolomab, Nacolomab tafenatox |
Navigation WikiDoc | WikiPatient | Popular pages | Recently Edited Pages | Recently Added
Pictures
There is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies
Table of Contents In Alphabetical Order | By Individual Diseases | Signs and Symptoms | Physical Examination | Lab Tests | Drugs
Editor Tools Become an Editor | Editors Help Menu | Create a Page | Edit a Page | Upload a Picture or File | Printable version | Permanent link | Maintain Pages | What Pages Link HereThere is no pharmaceutical or device industry support for this site and we need your viewer supported Donations | Editorial Board | Governance | Licensing | Disclaimers | Avoid Plagiarism | Policies